These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 23848154

  • 1. Structural investigations of recombinant urokinase growth factor-like domain.
    Beloglazova IB, Beabealashvilli RSh, Gursky YG, Bocharov EV, Mineev KS, Parfenova EV, Tkachuk VA.
    Biochemistry (Mosc); 2013 May; 78(5):517-30. PubMed ID: 23848154
    [Abstract] [Full Text] [Related]

  • 2. The kringle stabilizes urokinase binding to the urokinase receptor.
    Bdeir K, Kuo A, Sachais BS, Rux AH, Bdeir Y, Mazar A, Higazi AA, Cines DB.
    Blood; 2003 Nov 15; 102(10):3600-8. PubMed ID: 12881310
    [Abstract] [Full Text] [Related]

  • 3. The effects of amino-acid mutations on specific interactions between urokinase-type plasminogen activator and its receptor: Ab initio molecular orbital calculations.
    Tsuji S, Kasumi T, Nagase K, Yoshikawa E, Kobayashi H, Kurita N.
    J Mol Graph Model; 2011 Aug 15; 29(8):975-84. PubMed ID: 21605990
    [Abstract] [Full Text] [Related]

  • 4. Plasmin-dependent elimination of the growth-factor-like domain in urokinase causes its rapid cellular uptake and degradation.
    Poliakov A, Tkachuk V, Ovchinnikova T, Potapenko N, Bagryantsev S, Stepanova V.
    Biochem J; 2001 May 01; 355(Pt 3):639-45. PubMed ID: 11311125
    [Abstract] [Full Text] [Related]

  • 5. Ab initio molecular orbital calculations on specific interactions between urokinase-type plasminogen activator and its receptor.
    Nagase K, Kobayashi H, Yoshikawa E, Kurita N.
    J Mol Graph Model; 2009 Aug 01; 28(1):46-53. PubMed ID: 19403319
    [Abstract] [Full Text] [Related]

  • 6. The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain. Characterization of interactions and contribution to chemotaxis.
    Mukhina S, Stepanova V, Traktouev D, Poliakov A, Beabealashvilly R, Gursky Y, Minashkin M, Shevelev A, Tkachuk V.
    J Biol Chem; 2000 Jun 02; 275(22):16450-8. PubMed ID: 10749881
    [Abstract] [Full Text] [Related]

  • 7. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
    Magdolen V, Rettenberger P, Koppitz M, Goretzki L, Kessler H, Weidle UH, König B, Graeff H, Schmitt M, Wilhelm O.
    Eur J Biochem; 1996 May 01; 237(3):743-51. PubMed ID: 8647121
    [Abstract] [Full Text] [Related]

  • 8. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.
    Rasch MG, Pass J, Illemann M, Høyer-Hansen G, Lund IK.
    J Immunol Methods; 2008 Nov 30; 339(1):55-65. PubMed ID: 18761343
    [Abstract] [Full Text] [Related]

  • 9. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.
    Ploug M.
    Biochemistry; 1998 Nov 24; 37(47):16494-505. PubMed ID: 9843416
    [Abstract] [Full Text] [Related]

  • 10. Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143).
    Huang M, Mazar AP, Parry G, Higazi AA, Kuo A, Cines DB.
    Acta Crystallogr D Biol Crystallogr; 2005 Jun 24; 61(Pt 6):697-700. PubMed ID: 15930623
    [Abstract] [Full Text] [Related]

  • 11. Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction.
    Ploug M, Rahbek-Nielsen H, Ellis V, Roepstorff P, Danø K.
    Biochemistry; 1995 Oct 03; 34(39):12524-34. PubMed ID: 7548000
    [Abstract] [Full Text] [Related]

  • 12. Chemotactic effect of urokinase plasminogen activator: a major role for mechanisms independent of its proteolytic or growth factor domains.
    Poliakov AA, Mukhina SA, Traktouev DO, Bibilashvily RS, Gursky YG, Minashkin MM, Stepanova VV, Tkachuk VA.
    J Recept Signal Transduct Res; 1999 Nov 03; 19(6):939-51. PubMed ID: 10533982
    [Abstract] [Full Text] [Related]

  • 13. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
    Ploug M, Ostergaard S, Hansen LB, Holm A, Danø K.
    Biochemistry; 1998 Mar 17; 37(11):3612-22. PubMed ID: 9521680
    [Abstract] [Full Text] [Related]

  • 14. Structural basis of interaction between urokinase-type plasminogen activator and its receptor.
    Barinka C, Parry G, Callahan J, Shaw DE, Kuo A, Bdeir K, Cines DB, Mazar A, Lubkowski J.
    J Mol Biol; 2006 Oct 20; 363(2):482-95. PubMed ID: 16979660
    [Abstract] [Full Text] [Related]

  • 15. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V, Bürgle M, de Prada NA, Schmiedeberg N, Riemer C, Schroeck F, Kellermann J, Degitz K, Wilhelm OG, Schmitt M, Kessler H.
    Biol Chem; 2001 Aug 20; 382(8):1197-205. PubMed ID: 11592401
    [Abstract] [Full Text] [Related]

  • 16. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
    Skeldal S, Larsen JV, Pedersen KE, Petersen HH, Egelund R, Christensen A, Jensen JK, Gliemann J, Andreasen PA.
    FEBS J; 2006 Nov 20; 273(22):5143-59. PubMed ID: 17042782
    [Abstract] [Full Text] [Related]

  • 17. Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin.
    Franco P, Vocca I, Carriero MV, Alfano D, Cito L, Longanesi-Cattani I, Grieco P, Ossowski L, Stoppelli MP.
    J Cell Sci; 2006 Aug 15; 119(Pt 16):3424-34. PubMed ID: 16882693
    [Abstract] [Full Text] [Related]

  • 18. Critical role of integrin alpha 5 beta 1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling.
    Tarui T, Andronicos N, Czekay RP, Mazar AP, Bdeir K, Parry GC, Kuo A, Loskutoff DJ, Cines DB, Takada Y.
    J Biol Chem; 2003 Aug 08; 278(32):29863-72. PubMed ID: 12754207
    [Abstract] [Full Text] [Related]

  • 19. Activation of the zymogen to urokinase-type plasminogen activator is associated with increased interdomain flexibility.
    Behrens MA, Botkjaer KA, Goswami S, Oliveira CL, Jensen JK, Schar CR, Declerck PJ, Peterson CB, Andreasen PA, Pedersen JS.
    J Mol Biol; 2011 Aug 12; 411(2):417-29. PubMed ID: 21669207
    [Abstract] [Full Text] [Related]

  • 20. Binding of urokinase plasminogen activator to gp130 via a putative urokinase-binding consensus sequence.
    Liang OD, Chavakis T, Linder M, Bdeir K, Kuo A, Preissner KT.
    Biol Chem; 2003 Feb 12; 384(2):229-36. PubMed ID: 12675515
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.